BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 24022839)

  • 21. ALK-rearranged squamous cell lung carcinoma responding to crizotinib: A missing link in the field of non-small cell lung cancer?
    Vergne F; Quéré G; Andrieu-Key S; Descourt R; Quintin-Roué I; Talagas M; De Braekeleer M; Marcorelles P; Uguen A
    Lung Cancer; 2016 Jan; 91():67-9. PubMed ID: 26603857
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment.
    Camidge DR; Kono SA; Flacco A; Tan AC; Doebele RC; Zhou Q; Crino L; Franklin WA; Varella-Garcia M
    Clin Cancer Res; 2010 Nov; 16(22):5581-90. PubMed ID: 21062932
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer and related issues in ALK inhibitor therapy: a literature review.
    Yi ES; Chung JH; Kulig K; Kerr KM
    Mol Diagn Ther; 2012 Jun; 16(3):143-50. PubMed ID: 22506598
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment for ALK-mutated non-small-cell lung cancer: a new miracle in the research race.
    de Castro-Carpeño J; Perona R; Belda-Iniesta C
    Clin Transl Oncol; 2011 Nov; 13(11):774-9. PubMed ID: 22082640
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC.
    Casaluce F; Sgambato A; Maione P; Rossi A; Ferrara C; Napolitano A; Palazzolo G; Ciardiello F; Gridelli C
    Target Oncol; 2013 Mar; 8(1):55-67. PubMed ID: 23325296
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer.
    Karachaliou N; Santarpia M; Gonzalez Cao M; Teixido C; Sosa AE; Berenguer J; Rodriguez Capote A; Altavilla G; Rosell R
    Expert Opin Investig Drugs; 2017 Jun; 26(6):713-722. PubMed ID: 28463570
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
    Gettinger SN; Bazhenova LA; Langer CJ; Salgia R; Gold KA; Rosell R; Shaw AT; Weiss GJ; Tugnait M; Narasimhan NI; Dorer DJ; Kerstein D; Rivera VM; Clackson T; Haluska FG; Camidge DR
    Lancet Oncol; 2016 Dec; 17(12):1683-1696. PubMed ID: 27836716
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.
    Sasaki T; Koivunen J; Ogino A; Yanagita M; Nikiforow S; Zheng W; Lathan C; Marcoux JP; Du J; Okuda K; Capelletti M; Shimamura T; Ercan D; Stumpfova M; Xiao Y; Weremowicz S; Butaney M; Heon S; Wilner K; Christensen JG; Eck MJ; Wong KK; Lindeman N; Gray NS; Rodig SJ; Jänne PA
    Cancer Res; 2011 Sep; 71(18):6051-60. PubMed ID: 21791641
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment and detection of ALK-rearranged NSCLC.
    Peters S; Taron M; Bubendorf L; Blackhall F; Stahel R
    Lung Cancer; 2013 Aug; 81(2):145-54. PubMed ID: 23769207
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
    Cha YJ; Kim HR; Shim HS
    J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
    Ma D; Wang Z; Yang L; Mu X; Wang Y; Zhao X; Li J; Lin D
    Oncotarget; 2016 Sep; 7(39):64410-64420. PubMed ID: 27418132
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
    Shaw AT; Kim TM; Crinò L; Gridelli C; Kiura K; Liu G; Novello S; Bearz A; Gautschi O; Mok T; Nishio M; Scagliotti G; Spigel DR; Deudon S; Zheng C; Pantano S; Urban P; Massacesi C; Viraswami-Appanna K; Felip E
    Lancet Oncol; 2017 Jul; 18(7):874-886. PubMed ID: 28602779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma.
    Dacic S; Villaruz LC; Abberbock S; Mahaffey A; Incharoen P; Nikiforova MN
    Oncotarget; 2016 Dec; 7(50):82943-82952. PubMed ID: 27769042
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histologic and cytomorphologic features of ALK-rearranged lung adenocarcinomas.
    Nishino M; Klepeis VE; Yeap BY; Bergethon K; Morales-Oyarvide V; Dias-Santagata D; Yagi Y; Mark EJ; Iafrate AJ; Mino-Kenudson M
    Mod Pathol; 2012 Nov; 25(11):1462-72. PubMed ID: 22743652
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circulating Tumor Cells with Aberrant
    Pailler E; Oulhen M; Borget I; Remon J; Ross K; Auger N; Billiot F; Ngo Camus M; Commo F; Lindsay CR; Planchard D; Soria JC; Besse B; Farace F
    Cancer Res; 2017 May; 77(9):2222-2230. PubMed ID: 28461563
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?
    Toyokawa G; Seto T
    Clin Lung Cancer; 2014 Sep; 15(5):313-9. PubMed ID: 24984564
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnosis and Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.
    Arbour KC; Riely GJ
    Hematol Oncol Clin North Am; 2017 Feb; 31(1):101-111. PubMed ID: 27912826
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An Anaplastic Lymphoma Kinase Immunohistochemistry-Negative but Fluorescence In Situ Hybridization-Positive Lung Adenocarcinoma Is Resistant to Crizotinib.
    Shi R; Varella-Garcia M; Li M; Ludkovski O; Danesh A; Ng C; Pham NA; Pugh T; Shepherd FA; Tsao MS
    J Thorac Oncol; 2016 Dec; 11(12):2248-2252. PubMed ID: 27613526
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Investigation on the prognostic impact of concurrent genomic alterations in crizotinib-treated EML4-ALK-rearranged advanced non-small cell lung cancer patients.
    Zheng J; Zhu Y; Sun K; Shen Q; Wang Y; Cao H; Lizaso A; Yu B; Lin J; Chen S; Zhou J; Zhou J
    Lung Cancer; 2020 Aug; 146():209-216. PubMed ID: 32563740
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New strategies for treatment of ALK-rearranged non-small cell lung cancers.
    Sasaki T; Jänne PA
    Clin Cancer Res; 2011 Dec; 17(23):7213-8. PubMed ID: 22010214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.